Epidemiology of Mycoplasma pneumoniae Infections in Japan and Therapeutic Strategies for Macrolide-Resistant M. pneumoniae by Tsutomu Yamazaki & Tsuyoshi Kenri
fmicb-07-00693 May 19, 2016 Time: 12:27 # 1
REVIEW
published: 23 May 2016
doi: 10.3389/fmicb.2016.00693
Edited by:
Takeshi Saraya,
Kyorin University School of Medicine,
Japan
Reviewed by:
Shigeru Kamiya,
Kyorin University School of Medicine,
Japan
Lloyd Reeve-Johnson,
Queensland University of Technology,
Australia
*Correspondence:
Tsuyoshi Kenri
kenri@niid.go.jp
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 31 December 2015
Accepted: 26 April 2016
Published: 23 May 2016
Citation:
Yamazaki T and Kenri T (2016)
Epidemiology of Mycoplasma
pneumoniae Infections in Japan
and Therapeutic Strategies
for Macrolide-Resistant
M. pneumoniae.
Front. Microbiol. 7:693.
doi: 10.3389/fmicb.2016.00693
Epidemiology of Mycoplasma
pneumoniae Infections in Japan and
Therapeutic Strategies for
Macrolide-Resistant M. pneumoniae
Tsutomu Yamazaki1 and Tsuyoshi Kenri2*
1 Wakaba Children’s Clinic, Saitama, Japan, 2 Laboratory of Mycoplasmas and Haemophilus, Department of Bacteriology II,
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Pneumonia caused by Mycoplasma pneumoniae (M. pneumoniae pneumonia) is
a major cause of community-acquired pneumonia worldwide. The surveillance of
M. pneumoniae pneumonia is important for etiological and epidemiological studies
of acute respiratory infections. In Japan, nation-wide surveillance of M. pneumoniae
pneumonia has been conducted as a part of the National Epidemiological Surveillance
of Infectious Diseases (NESID) program. This surveillance started in 1981, and significant
increases in the numbers of M. pneumoniae pneumonia patients were noted in 1984,
1988, 2006, 2010, 2011, 2012, and 2015. The epidemics in 2011 and 2012 were
particularly widespread and motivated researchers to conduct detailed epidemiological
studies, including genotyping and drug resistance analyses of M. pneumoniae isolates.
The genotyping studies based on the p1 gene sequence suggested that the p1 gene
type 1 lineage has been dominant in Japan since 2003, including the epidemic period
during 2011–2012. However, more detailed p1 typing analysis is required to determine
whether the type 2 lineages become more relevant after the dominance of the type 1
lineage. There has been extensive research interest in implications of the p1 gene types
on the epidemiology of M. pneumoniae infections. Serological characterizations of sera
from patients have provided a glimpse into these associations, showing the presence
of type specific antibody in the patient sera. Another important epidemiological issue
of M. pneumoniae pneumonia is the emergence of macrolide-resistant M. pneumoniae
(MRMP). MRMPs were noted among clinical isolates in Japan after 2000. At present,
the isolation rate of MRMPs from pediatric patients is estimated at 50–90% in Japan,
depending on the specific location. In view of the situation, Japanese societies have
issued guiding principles for treating M. pneumoniae pneumonia. In these guiding
principles, macrolides are still recommended as the first-line drug, however, if the fever
does not subside in 48–72 h from first-line drug administration, a change of antibiotics
to second-line drugs is recommended.
Keywords: Mycoplasma pneumoniae, community-acquired pneumonia, infectious diseases surveillance, periodic
epidemics, P1 cytadhesin, P1 typing, hemadsorption, macrolide resistance
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SURVEILLANCE OF M. pneumoniae
PNEUMONIA IN JAPAN
In Japan, the National Epidemiological Surveillance of Infectious
Diseases (NESID) program is conducted under the Infectious
Diseases Control Law (Law Concerning the Prevention of
Infectious Diseases and Medical Care for Patients of Infections),
which includes nationwide surveillance of pneumonia cases
caused by Mycoplasma pneumoniae. M. pneumoniae pneumonia
is classified as a category V infectious disease in the NESID,
and the numbers of affected patients (total of outpatients
and inpatients) are reported weekly from sentinel hospitals.
Approximately 500 hospitals across Japan that have departments
of pediatrics and internal medicine and more than 300 beds
are currently selected as the sentinels for surveillance of
M. pneumoniae pneumonia in Japan. For notification of each
new M. pneumoniae pneumonia patient, confirmation is required
using one of the tests listed in Table 1 in addition to clinical
symptoms observed by a clinician. Previously, culture isolation
of M. pneumoniae and detection of serum antibodies against
M. pneumoniae were employed as the tests for notification.
However, detection of M. pneumoniae genomic DNA by
polymerase chain reaction (PCR) or loop-mediated isothermal
amplification (LAMP) and detection of M. pneumoniae antigens
by immuno-chromatographic methods have been recently
included in the tests for notification1. The data from sentinels
are integrated at the Infectious Disease Surveillance Center
(IDSC), National Institute of Infectious Diseases (NIID) and
published weekly2. Since the NESID program was initiated in
July 1981, the surveillance of primary atypical pneumonia (PAP)
was continuously performed until March 1999. The criteria of
PAP include pneumonia other than M. pneumoniae pneumonia,
such as that caused by Chlamydophila pneumoniae, Legionella
pneumophila, or several viruses. However, as the major cause
of PAP is M. pneumoniae, this surveillance largely represented
1http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-38.html
2http://www.nih.go.jp/niid/ja/10/2096-weeklygraph/1659-18myco.html
TABLE 1 | Tests required for notification of Mycoplasma pneumoniae
pneumonia from sentinel clinics.
Test (Method) Specimen
Isolation of M. pneumoniae (Culture
method)
Specimens derived from the patient’s
respiratory tract
Detection of M. pneumoniae antigen
(Immuno-chromatographic method)a
Detection of M. pneumoniae DNA
(PCR, LAMP, etc.)b
Detection of antibody (serological
diagnosis)
Serum
aFour commercial immuno-chromatographic diagnosis kits for M. pneumoniae
have been approved and used in Japan since 2013: Prime check MycoplasmaTM
(Alfresa Parma), Ribotest MycoplasmaTM (Asahi Kasei), Prorast MycoTM (LSI
Medience), and Immuno Ace MycoplasmaTM (Tauns Laboratories). The detection
targets of these four kits are P1 adhesin, ribosomal L7/L12, DnaK and P30
proteins, respectively. bGenomic DNA detection tests have been introduced to the
surveillance since 2011.
the general trend of mycoplasma epidemics. As of April 1999,
M. pneumoniae pneumonia-specific surveillance was initiated
by NESID under the revised Infectious Diseases Control Law.
Figure 1 shows the most recent M. pneumoniae pneumonia
surveillance data collected by the NESID. In the early period
of data collection, there were large increases of PAP patients
observed in 1984 and 1988. Before the NESID surveillance
was started in Japan, an extensive epidemiological study of
M. pneumoniae pneumonia in school children was performed
in the 1960s and 1970s in Sendai city (Niitu, 1984). In this
study, an increase of M. pneumoniae pneumonia patients was
observed every 4 years (i.e., 1964, 1968, 1972, and 1976),
suggesting periodicity in the epidemics of this disease. Epidemics
observed by the NESID in 1984 and 1988 (Figure 1) are
compatible with this 4-year periodicity pattern observed in
Sendai city. Given that these 4-year-cycle epidemics occurred
in Olympic years, M. pneumoniae pneumonia has often been
referred to as “Olympic disease” in Japan. However, after this
period, 4-year-cycle epidemics were no longer observed in the
NESID surveillance, although slight increases in the number
of patients were observed in 1992 and 1996. The reason for
disappearance of periodic epidemic is unknown, however, it
is noteworthy that clarithromycin has been introduced for
treatment of PAP since 1991. After 2000, M. pneumoniae
pneumonia epidemics were observed in 2006, 2010, 2011,
and 2012. The epidemics in 2011 and 2012 were particularly
widespread and attracted public attention. Although the reason
for these large epidemics in 2011 and 2012 is unknown,
large increases in the numbers of M. pneumoniae pneumonia
patients were also reported in Europe and other countries
during this period (Chalker et al., 2011; Blystad et al., 2012;
Nir-Paz et al., 2012; Pereyre et al., 2013; Kim et al., 2015).
After these large epidemics in 2011 and 2012, the number of
M. pneumoniae pneumonia patients decreased rapidly, and was
quite low in 2014. However, the number of patients increased
again since the summer of 2015 and reached a higher level
during the winter (Figures 1 and 2). An increase of patient
number was also reported in China in 2015 (Yan et al.,
2016).
Such period occurrences of M. pneumoniae pneumonia
epidemics in 3–7-year intervals has been observed in
surveillances of M. pneumoniae pneumonia in many areas
of the world (Lind and Bentzon, 1976; Foy et al., 1979; Lind
et al., 1997; Rastawicki et al., 1998; Ito et al., 2001; Eun et al.,
2008; Chalker et al., 2011; Blystad et al., 2012; Youn and Lee,
2012; Kim et al., 2015). This phenomenon is considered to be
one of the characteristic features of this disease. One potential
reason for the pattern of periodic epidemics of M. pneumoniae
pneumonia may be related to interactions between the pathogen
and the immunological status of the human population (Fernald
and Clyde, 1970; Mogabgab et al., 1975; Hayatsu et al., 1981;
Leith et al., 1983; Barile et al., 1994). Once M. pneumoniae
pneumonia epidemics occur, protective immunity may arise
in the human population. However, this protective immunity
may not last long, and the next generation will be dominated by
younger individuals who had not been exposed, and thus do not
have the protective immunity. In this situation, M. pneumoniae
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become active and may cause the next epidemic. A mathematical
model of this process was recently reported (Omori et al.,
2015). There are also reports of weather factors that might
affect M. pneumoniae infections (Onozuka et al., 2009; Onozuka
and Chaves, 2014). Examination of the NESID data from a
seasonal perspective shows that the number of M. pneumoniae
pneumonia patients generally increases in autumn and winter
every year. However, depending on the year, small increases
are sometimes also observed in early summer (Figure 2). From
a regional view, the number of patients varies according to
FIGURE 1 | Weekly cases of primary atypical pneumonia (from April 1981 to March 1999, red line) and Mycoplasma pneumoniae pneumonia (from
April 1999 to present, blue line) in Japan reported by The National Epidemiological Surveillance of Infectious Diseases (NESID).
FIGURE 2 | Weekly cases of M. pneumoniae pneumonia in Japan between 1999 and 2015 reported by the NESID. http://www.nih.go.jp/niid/ja/10/2096-
weeklygraph/1659-18myco.html.
Frontiers in Microbiology | www.frontiersin.org 3 May 2016 | Volume 7 | Article 693
fmicb-07-00693 May 19, 2016 Time: 12:27 # 4
Yamazaki and Kenri Mycoplasma pneumoniae Infections in Japan
prefectures in Japan. In the 2011 and 2012 epidemic period,
the numbers of patients increased in most of the prefectures
compared to those in previous years (Figure 3). Approximately
80% of M. pneumoniae pneumonia patients in Japan are in the
1–14-year-old age group, although M. pneumoniae pneumonia
occurs in all age groups.
The national surveillance of M. pneumoniae pneumonia
in the NESID program is based on reports from sentinel
hospitals, and is thus not a survey of the total number
of patients with this disease. Since the sentinels are large
hospitals, information of M. pneumoniae pneumonia patients
who are diagnosed and treated in small outpatient clinics
is not included in the NESID data. The NESID also does
not provide molecular epidemiological data or drug resistance
information of M. pneumoniae clinical isolates. Although these
issues need to be addressed, the weekly surveillance data
provided by the NESID is nevertheless useful and functions
as an alert for public health workers, medical institutions, and
researchers. The NESID data allow for researchers to conduct
detailed epidemiological studies to grasp the actual situation of
M. pneumoniae infections, including molecular epidemiological
and drug resistance aspects of this infectious disease, especially
when the signs of epidemics are observed in the surveillance
data.
MOLECULAR EPIDEMIOLOGY
In general, M. pneumoniae clinical isolates can be classified into
two distinct genetic lineages (type 1 and 2 lineages) based on
their genomic background (Simmons et al., 2013; Brown et al.,
2015; Lluch-Senar et al., 2015; Touati et al., 2015; Xiao et al.,
2015). The p1 gene, which encodes the major cytadhesin P1
protein, exhibits sequence polymorphism between the type 1 and
2 lineages (Su et al., 1990; Kenri et al., 1999; Spuesens et al.,
2010; Zhao et al., 2011; Dumke et al., 2015). The p1 types were
also referred as the p1 subtypes or groups in previous studies.
A number of typing analyses of M. pneumoniae isolates based
on p1 gene polymorphism have been reported to date (Jacobs
et al., 1996; Sasaki et al., 1996; Cousin-Allery et al., 2000; Kenri
et al., 2008; Dumke et al., 2010b; Liu et al., 2010; Martinez
et al., 2010). In our previous study, we genotyped M. pneumoniae
isolated mainly in Kanagawa prefecture, Japan, and found that
the rate of p1 types 1 and 2 detection was not constant but rather
varied year by year (Figure 4) (Sasaki et al., 1996; Kenri et al.,
2008). In brief, type 2 was dominant in the early 1980s, 1990s,
and at the beginning of the 2000s, while type 1 was dominant
in the late 1980s and after 2003. This study demonstrated an
alternative type-shift phenomenon of M. pneumoniae p1 types
with intervals of about 10 years. The time dependency of the
FIGURE 3 | Incidence of M. pneumoniae pneumonia in Japan by prefecture reported by the NESID. The ranges of the number of cases in each prefecture
(annual cases per sentinel) are shown in different colors. The figure is adapted from Infectious Agents Surveillance Report (IASR), 33 (10), 2012. http://www.nih.go.
jp/niid/en/iasr-vol33-e/865-iasr/2738-tpc392.html.
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FIGURE 4 | Typing analysis of the M. pneumoniae p1 gene from isolates detected in Japan between 1976 and 2005. The majority of M. pneumoniae
strains and clinical specimens included in this analysis were collected in the Kanagawa prefecture. Figure adapted from Kenri et al. (2008).
rate of types 1 and 2 of the p1 gene on the study period has
also been observed in isolates from other parts of the world;
however, no reports have shown a clear type-shift pattern similar
to that observed in Kanagawa prefecture (Cousin-Allery et al.,
2000; Pereyre et al., 2007; Martinez et al., 2010; Spuesens et al.,
2012; Diaz et al., 2015; Kogoj et al., 2015). In typing analyses
of isolates in Germany, the rate of types 1 and 2 detection was
found to be relatively constant during the research period of
about 10 years including the epidemics in 2011–2013 (Dumke
et al., 2010b, 2015; Jacobs et al., 2015). The relationship between
M. pneumoniae pneumonia epidemics and two type lineages of
M. pneumoniae remains unclear (Jacobs et al., 1996, 2015; Kenri
et al., 2008).
According to several p1 typing studies, the dominant
M. pneumoniae in Japan has been considered to be type 1 strains
since 2003 (Fujii et al., 2012; Horino, 2012; Ohya et al., 2012;
Ishiguro et al., 2015; Kubota et al., 2015; Suzuki et al., 2015).
Apparent p1 type shift of M. pneumoniae clinical strains was not
observed during the large epidemic period in 2011 and 2012.
For example, 126 M. pneumoniae strains were isolated at the
Kanagawa Prefectural Institute of Public Health between 2003
and 2011. Of these, 101 (80%) were type 1, 7 (6%) were type
2, and 18 (14%) were type 2 variants (Ohya et al., 2012). At
the Yamagata Prefectural Institute of Public Health, 358 isolates
were genotyped between 2004 and 2013. Of these, 278 (77.7%)
were type 1, 10 (2.8%) were variant 2a, 5 (1.4%) were variant 2b,
and 65 (18.2%) were variant 2c. No type 2 strain was detected
in Yamagata. In the case of Yamagata, type 1 accounted for
85–100% of the annual isolates recorded between 2004 and
2011. However, the isolation rate of type 1 reduced to 73.5%
(83/113) and 33.9% (21/62) in 2012 and 2013, respectively. The
proportion of variant 2c isolates increased in 2012 and 2013, as
a counterpart of type 1 (Suzuki et al., 2015). At this point, it
is not clear whether this is the sign of p1 type change in this
area. Although type 1 is considered to be dominant across a
wide area of Japan at present, there is a report of a local area
where type 2 is prevalent (Ishiguro et al., 2015). Most of type
2 lineage strains isolated in Japan in recent years are variants
2a and 2c while variant 2b and type 2 strains are rare. Type
2 was frequently found among the clinical isolates before 2000
(Figure 4), but type 2 was replaced by its variants (2a and 2c)
almost completely during the last decade. The dominance of
type 1 was also reported in recent clinical isolates in China and
France (Liu et al., 2010; Wang et al., 2012; Pereyre et al., 2013;
Tian et al., 2013; Zhao et al., 2013a; Xiao et al., 2014; Xue et al.,
2014; Zhou et al., 2015). The results of a recent study conducted
in Beijing, China indicate an increasing trend of type 2 lineage
(Zhao et al., 2015), although it is not yet clear whether the type-
shift phenomenon from type 1 to 2 is occurring. Further p1 typing
analysis is needed to explore whether type 2 lineage strains might
become prevalent in the future in areas where type 1 are currently
dominant.
Multilocus variable-number tandem-repeat analysis (MLVA)-
based typing is a newly developed strategy for molecular
epidemiological analyses of M. pneumoniae (Degrange et al.,
2009; Chalker et al., 2015). Several reports demonstrated that
Japanese clinical isolates can be also separated into multiple
MLVA types as same as the clinical strains isolated in the other
areas (Degrange et al., 2009; Kubota et al., 2015; Touati et al.,
2015). However, more MLVA typing studies are needed to discuss
the characteristic profiles of Japanese strains in terms of this
typing method.
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FIGURE 5 | Western blotting of the sera from M. pneumoniae pneumonia patients against recombinant P1 antigens. (A) Schematic illustration of the P1
protein structure. P1 is a 170-kDa membrane protein consisting of about 1,630 amino acids (aa) depending on the strains. The first 59 aa of this protein (hatched
box) is a leader peptide, which is removed during maturation. The two gray boxes indicate polymorphic regions of P1 protein that exhibit amino acid sequence
variation between type 1 and 2 strains. RepMP4 and RepMP2/3 indicate repetitive regions of the p1 gene. Multiple copies of DNA sequences similar to the RepMP4
and RepMP2/3 regions are present throughout the M. pneumoniae genome. The three filled boxes indicate the positions of recombinant P1 protein fragments
produced in E. coli. The rP1-N1 region corresponds to aa 218 to 352 of the P1 protein of M129 strain (type 1). The rP1-N2 region corresponds to aa 218 to 357 of
the P1 protein of FH strain (type 2). The rP1-8 region corresponds to aa 1160 to 1518 of M129 P1 (Kenri et al., 2006b). (B) Western blotting of patient sera against
rP1-N1, rP1-N2, and rP1-8 recombinant proteins. Purified rP1-N1, rP1-N2, and rP1-8 proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and were blotted on a nitrocellulose membrane. Diluted (100-fold) serum samples from nine patients and two healthy subjects were reacted with the
membrane. IgGs bound to the membrane were detected by alkaline phosphatase-conjugated anti-human IgG secondary antibody. The positions of recombinant P1
protein fragments are shown on the left. Lane M: Coomassie Brilliant Blue stain of the blotted membrane; lanes 1–10: patient sera (serum samples of lanes 5 and 9
were obtained from the same patient in an interval of 1 week); lanes 11 and 12: serum from healthy subjects. Types of p1 genes detected by the nested PCR
method (Kenri et al., 2008) from the sputum of same patient are shown on the bottom. The analyses of serum and sputum samples were performed as a part of
previous studies (Yamazaki et al., 2006; Kenri et al., 2008).
SEROLOGICAL CHARACTERIZATION OF
M. pneumoniae PNEUMONIA PATIENT
SERA AGAINST TYPE 1 AND 2 P1
PROTEINS
P1 cytadhesin is one of the major antigens of M. pneumoniae
that induce antibody production. Indeed, the anti-P1 antibody
is frequently detected in the sera of M. pneumoniae pneumonia
patients (Hirschberg et al., 1991; Razin and Jacobs, 1992;
Rastawicki et al., 1996; Tuuminen et al., 2001). Since the P1
protein exhibits amino acid sequence polymorphism between the
type 1 and 2 lineages, there was a possibility that P1 proteins
of types 1 and 2 have different immunogenicity and induce
specific antibodies during infection. In support of this idea,
there are reports of the production of a monoclonal antibody
that specifically recognizes type 1 P1 protein (Gerstenecker and
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Jacobs, 1990; Jacobs et al., 1996), and induction of type-specific
immunity was achieved with P1 fragment antigens in guinea
pigs (Dumke et al., 2008). To obtain more evidence for specific
immunological responses to the two P1 types, we engineered
and produced three recombinant P1 protein fragments, shown
in Figure 5A. The amino acid sequences of the rP1-N1 and rP1-
N2 regions are derived from P1 protein of the strains M129
(type 1) and FH (type 2), respectively (Kenri et al., 2006a,b).
These regions exhibit the highest differences between type 1
and 2 P1 proteins, whereas the amino acid sequence of rP1-
8 region is identical between type 1 and 2 P1 proteins. Using
these three P1 fragments as antigens, we performed a western
blotting analysis of the sera of nine M. pneumoniae pneumonia
patients to detect anti-P1 IgG (Figure 5B). The patient sera
chosen for this western blot were those that exhibited high
antibody titers in the serological diagnosis for M. pneumoniae
pneumonia (see Table 2). Furthermore, p1 genes were detected
from sputum samples of the same patients and were genotyped
by PCR (Figure 5B and Table 2). This information indicates
the most probable type of M. pneumoniae that infected the
patients. The western blot result is shown in Figure 5B. All
of the patient sera exhibited similar reactivity against the rP1-
8 fragment, whereas the reactivity against rP1-N1 and rP1-N2
varied depending on the serum sample (Figure 5B). The sera
from patients whose sputa were type 1 p1-positive in PCR
showed stronger reactivity against rP1-N1 (Figure 5B, lanes
1–4, 8, and 10). On the other hand, the sera from patients
with type 2 p1-positive sputa exhibited stronger reactivity
against rP1-N2 (Figure 5B, lanes 5, 6, and 9) except for one
serum (Figure 5B, lane 7). One of the serum samples from
a healthy subject, used as a negative control, also showed
weak reactivity against rP1-8 and rP1-N2 (Figure 5B, lane
11). This individual most likely had a previous, and perhaps
unnoticed, infection with type 2 M. pneumoniae. These results
demonstrated that induction of type-specific anti-P1 antibodies
occurs in humans during M. pneumoniae infection (Kenri et al.,
2006a,b).
HEMADSORPTION (HA) INHIBITORY
ACTIVITY OF M. pneumoniae
PNEUMONIA PATIENT SERA
It has been reported that M. pneumoniae pneumonia patient
sera exhibit inhibitory activity toward the adsorption of red
blood cells to M. pneumoniae colonies [i.e., hemadsorption (HA)
inhibitory activity; Hirschberg et al., 1991; Razin and Jacobs,
1992; Rastawicki et al., 1996; Tuuminen et al., 2001; Schurwanz
et al., 2009]. Thus, we examined the HA inhibitory activity
of the patient sera analyzed by western blotting in Figure 5B,
and the results are shown in Table 2. The sera from type 1-
infected patients (No. 1–4, 8, and 10) tended to show stronger
HA inhibitory activity against M129 strain (type 1). On the
other hand, the sera from type 2-infected patients (No. 5, 6,
and 9) exhibited stronger HA inhibitory activity against FH
strain (type 2) compared to M129. This result indicated that
M. pneumoniae pneumonia patient sera with a high antibody
titer possessed type-specific HA inhibitory activities (Kenri et al.,
TABLE 2 | Hemadsorption inhibitory activity of patient and non-patient sera.
Serum No.a Antibody titerb p1 gene types detected from patient sputac Hemadsorption (HA) inhibitory activityd
M129 (Type 1) FH (Type 2)
1/5 1/10 1/5 1/10
1 1280 1 + ± – –
2 2560 1 + ± ± –
3 1280 1 + + + ±
4 >2560 1 + + – –
5 >2560 2 ± – + ±
6 >2560 2 ± – + ±
7 1280 2 ± – ± –
8 >2560 1 + + – –
9 1280 2 ± – + ±
10 >2560 1 + – – –
11 ND NT – – – –
12 ND NT – – – –
aSerum number corresponds to the lane number of Figure 5B. bAntibody titer was measured with Serodia Myco II kit (Fujirebio, Tokyo, Japan); ND, not determined.
cDetection and typing of the p1 gene was performed by the nested PCR method as a part of previous study (Kenri et al., 2008); NT, not tested. dFive to ten colonies
of M. pneumoniae M129 (type 1) or FH (type 2) strains were formed on PPLO agar cast in a 24-well microplate (1.5 ml PPLO agar per well). Colony-forming wells were
soaked with 1 ml of phosphate-buffered saline (PBS) for 5 min at room temperature. After removal of PBS, 0.1 ml of diluted patient serum (fivefold or 10-fold dilution by
PBS) was added to the well and incubated for 20 min at 37◦C. After removal of the patient serum, 0.5 ml of a diluted sheep red blood cell (RBC) suspension (100-fold
dilution by PBS) was added to the well and incubated for 20 min at 37◦C. After incubation, excess RBCs were removed by washing with 1 ml of PBS three times.
The state of hemadsorption of M. pneumoniae colonies was evaluated by microscopic observation. +: complete hemadsorption inhibition (no adsorption of RBCs was
observed); ±: partial inhibition (partial adsorption of RBCs was observed); –: no inhibition (colonies were fully covered by RBCs; Kenri et al., 2006b).
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2006a,b). Indeed, some anti-P1 antibodies have been reported
to show HA inhibitory activity (Krause and Baseman, 1983;
Jacobs et al., 1989; Gerstenecker and Jacobs, 1990); however,
it is not clear whether the type-specific anti-P1 antibodies
detected in the western blotting in Figure 5B play a role
in determining the type-specific HA inhibitory activity. It is
possible that antibodies against another type-specific antigen are
responsible for the observed type-specific HA inhibitory activity.
If these type-specific HA inhibitory activities of patient sera
serve as protective immunity for M. pneumoniae infection, this
might explain the type shift phenomenon of M. pneumoniae
isolates.
EMERGENCE OF
MACROLIDE-RESISTANT
M. pneumoniae (MRMP)
It has been known at least since the 1970s that M. pneumoniae
can acquire resistance against macrolides relatively easily in
laboratory culture (Niitu et al., 1970; Nitu et al., 1974; Lucier
et al., 1995; Pereyre et al., 2004). There are also some early
reports of MRMP clinical isolates (Stopler et al., 1980; Clara
et al., 1989). However, MRMPs rapidly and broadly spread
after 2000, especially in eastern Asian countries such as China,
Korea, and Japan (Okazaki et al., 2001; Matsuoka et al., 2004;
Morozumi et al., 2005, 2008; Cao et al., 2010; Bebear et al., 2011;
Hong et al., 2013; Zhao et al., 2013b, 2014). The frequencies
of MRMP detection are now increasing in other areas of the
world (Pereyre et al., 2007; Li et al., 2009; Peuchant et al.,
2009; Dumke et al., 2010a; Averbuch et al., 2011; Chironna
et al., 2011; Yamada et al., 2012; Eshaghi et al., 2013; Tsai
et al., 2013; Wu et al., 2013; Caballero Jde et al., 2014; Saraya
et al., 2014; Diaz et al., 2015; Zheng et al., 2015). MRMPs
are isolated more frequently from adolescent and pediatric
patients than from adults, which is likely related to the frequent
use of macrolides for treatments of mycoplasmal infections
at younger ages. However, isolation of MRMPs from adult
patients is also on the rise (Isozumi et al., 2009; Miyashita
et al., 2012; Yoo et al., 2012; Hanada et al., 2014; Zhou et al.,
2015). Most of the MRMPs isolated in Japan carry the A2063G
mutation in domain V of the 23S rRNA gene that confers strong
resistance to 14- and 15-membered macrolides and lincosamides.
However, there is a report of a local outbreak caused by MRMPs
carrying the A2063T mutation, which exhibits only moderate
resistance to macrolides (Suzuki et al., 2013). The most recent
estimate of the isolation rate of MRMPs from adolescent and
pediatric patients in Japan is 50–90%, depending on the area
(Morozumi et al., 2008; Akaike et al., 2012; Miyashita et al.,
2012; Kawai et al., 2013b; Ishiguro et al., 2015). Given this
situation, the Japan Pediatric Society3 and The Japanese Society
for Mycoplasmology4 have issued guiding principles for treating
M. pneumoniae pneumonia (The committee on the guiding
3http://www.jpeds.or.jp/uploads/files/saisin_130219_2.pdf
4http://square.umin.ac.jp/jsm/shisin.pdf
principle for treatment of Mycoplasma pneumoniae pneumonia,
2014).
THERAPEUTIC STRATEGIES FOR
M. pneumoniae PNEUMONIA
Mycoplasma pneumoniae is generally susceptible to macrolides,
tetracyclines, and the new quinolone antibiotics. However, as
stated above, the emergence of MRMP since 2000 has made the
treatment of M. pneumoniae pneumonia challenging. Although
MRMP strains have been reported in European countries and
in the United States, the detection rates from these countries
are lower than those in East Asia, including Japan. Caution in
monitoring and treating MRMP strains and the necessity of
continuous surveillance for these strains are partially described
in the guidelines of the Infectious Diseases Society of America
(IDSA), American Thoracic Society (ATS; Mandell et al., 2007),
European Respiratory Society, European Society for Clinical
Microbiology and Infectious Diseases for adults (Woodhead
et al., 2011), and in the Pediatric Infectious Diseases Society
(PIDS) and IDSA for children (Bradley et al., 2011). However,
the necessity and strategies of alternative antibiotic treatment for
MRMP strains have not been described in detail. The detection
rates of MRNPs are associated with age (Miyashita et al., 2013):
detection rates are higher in children aged ≤15 years than
in adults. In addition, the detection rates among adults are
higher in adolescents aged 16–19 years than in those aged
≥20 years.
The guidelines of the IDSA and ATS recommend macrolides
or tetracyclines as the first-line drugs for M. pneumoniae
pneumonia, and fluoroquinolones as the second-line drugs in
adults. The guidelines of the PIDS and IDSA for children
recommend azithromycin as the first-line oral drug, and
clarithromycin, erythromycin, or doxycycline (for patients aged
≥8 years) along with levofloxacin or moxifloxacin (for adolescent
patients) as the second-line oral drugs, for mild cases. For
treatment via injection, azithromycin is recommended as the
first-line drug (although this is not indicated for children in
Japan), and erythromycin and levofloxacin (also not indicated
for children in Japan) are recommended as the second-line
drugs.
Thus, the applicability of antibiotics differs between adults
and children; in addition, the indication for antibiotics for
children is different between Japan and other countries. In
view of these points, the therapeutic guiding principles3,4 for
M. pneumoniae pneumonia issued in Japan are reviewed in the
following sections.
Treatment in Adults: Recommendations
by the Japanese Society of
Mycoplasmology
The first-line drugs for M. pneumoniae pneumonia in adults
are macrolide antibiotics. Oral administration of clarithromycin
(400 mg/day administered in two divided doses) or erythromycin
(800–1,200 mg/day administered in 4–6 divided doses for
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7–10 days) is recommended for patients on an outpatient
basis. Oral azithromycin administered at 500 mg once a
day for 3 days or at 2 g once a day for 1 day is also
indicated (Table 3). The minimum inhibitory concentration
(MIC) values of macrolides for M. pneumoniae without
macrolide resistance genes are extremely low, while those of
fluoroquinolones and tetracyclines are higher (Akaike et al.,
2012). Minocycline, levofloxacin, garenoxacin, moxifloxacin,
sitafloxacin, and tosufloxacin are recommended as second-line
drugs (Table 3). Intravenous administration is indicated for
inpatients: minocycline, azithromycin, and erythromycin are
recommended as first-line drugs, and levofloxacin, ciprofloxacin,
and pazufloxacin are recommended as the second-line drugs
(Table 4).
There is concern surrounding the emergence of quinolone
resistance in Streptococcus pneumoniae and other respiratory
pathogenic bacteria owing to the use of quinolones as the
initial treatment for pneumonia. Quinolones have been shown
capable of inducing resistance in M. pneumoniae strains
in vitro (Gruson et al., 2005). Therefore, quinolones should
be avoided during the initial treatment in young patients
TABLE 3 | Recommended treatments for adult outpatients of
M. pneumoniae pneumonia.
Drug Route of
administration
mg/dose Dose/
day
First-line drug Clarithromycin (CAM) Oral 200 2
Azithromycin (AZM)
(Slow-release formulation)
Oral 2000 1 (1 day)
Azithromycin (AZM) Oral 500 1 (3 days)
Erythromycin (EM) Oral 200 4–6
Second-line
drug
Minocycline (MINO) Oral 100 2
Levofloxacin (LVFX) Oral 500 1
Garenoxacin (GRNX) Oral 400 1
Moxifloxacin (MFLX) Oral 400 1
Sitafloxacin (STFX) Oral 100 2
Oral 200 1
Tosufloxacin (TFLX) Oral 150 2–3
The table is adapted from the guiding principle (Chiryo–Shishin) issued
by the Japanese Society of Mycoplasmology (JSM). http://square.umin.ac.jp/jsm/
shisin.pdf.
TABLE 4 | Recommended treatments for adult inpatients of
M. pneumoniae pneumonia.
Drug Route of
administration
mg/dose Dose/
day
First-line
drug
Minocycline (MINO) Intravenous (drip infusion) 100 2
Azithromycin (AZM) Intravenous (drip infusion) 500 1
Erythromycin (EM) Intravenous (drip infusion) 300–500 2–3
Second-
line
drug
Levofloxacin (LVFX) Intravenous (drip infusion) 500 1
Ciprofloxacin (CPFX) Intravenous (drip infusion) 300 2
Pazufloxacin (PZFX) Intravenous (drip infusion) 500–1000 2
The table is adapted from the guiding principle of JSM (http://square.umin.ac.jp/
jsm/shisin.pdf).
with suspected M. pneumoniae pneumonia. M. pneumoniae
pneumonia is less common in the elderly than in the
younger generation. Quinolones are prescribed for elderly
patients with pneumonia, because microorganisms other
than M. pneumoniae are typically involved. On the other
hand, tetracyclines are not likely to induce resistance in
M. pneumoniae. Intravenous administration of tetracycline
is recommended as the first-line treatment for hospitalized
patients (Table 4). Although there is no sufficient evidence
regarding the duration of antibiotic administration for
the treatment of M. pneumoniae pneumonia in adults, the
Japanese Society of Mycoplasmology recommends a duration of
7–10 days.
When the fever does not subside within 48–72 h after the
administration of macrolides, the antibiotics should be changed
considering the possibility of MRMP involvement. At present,
MRMP is susceptible to both tetracyclines and fluoroquinolones.
A study of the treatment for infection with MRMP in children
demonstrated that minocycline showed a higher rate of bacterial
elimination than tosufloxacin, and the fever subsided faster upon
treatment with minocycline than with tosufloxacin (Kawai et al.,
2013a).
Considering the emergence of quinolone resistance, the first-
line drug recommended for MRMP pneumonia is minocycline
(Table 5). Oral minocycline administered at 200 mg/day in
two divided doses on an outpatient basis, and intravenous
minocycline administered at 100 mg twice a day for inpatients
is recommended. Quinolones are recommended as second-
line drugs for both outpatients and inpatients (Tables 5
and 6). For outpatient treatment, levofloxacin, garenoxacin,
moxifloxacin, sitafloxacin, or tosufloxacin is orally administered
(Tables 3 and 5). For inpatient treatment, levofloxacin,
ciprofloxacin, or pazufloxacin is intravenously administered
(Tables 4 and 6). The duration of antibiotic treatment is 7–
10 days, similar to that for infection with macrolide-sensitive
M. pneumoniae.
In severe cases of M. pneumoniae pneumonia involving
respiratory failure, methylprednisolone is administered at 500–
1,000 mg/day for 3–5 days concomitantly with an appropriate
antimycoplasmal drug. It should be noted that the relationship
between MRMP and severe M. pneumoniae infection remains
unclear.
Treatment in Children:
Recommendations by the Japanese
Society of Pediatric Pulmonology,
Japanese Society for Pediatric Infectious
Diseases, Japan Pediatric Society, and
Japanese Society of Mycoplasmology
Macrolides are also recommended as the first-line drugs for
M. pneumoniae pneumonia in children. The incidence of
MRMP isolates from pediatric cases varies both regionally and
epidemically in Japan, ranging from <50% in patients without
a history of macrolide treatment to >90% in patients that were
treated by macrolides without clinical effectiveness. The MIC
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TABLE 5 | Recommended treatments for adult outpatients of
macrolide-resistant M. pneumoniae pneumonia.
Drug Route of
administration
mg/dose Dose/
day
First-line drug Minocycline (MINO) Oral 100 2
Second-line
drug
Levofloxacin (LVFX) Oral 500 1
Garenoxacin (GRNX) Oral 400 1
Moxifloxacin (MFLX) Oral 400 1
Sitafloxacin (STFX) Oral 100 2
200 1
Tosufloxacin (TFLX) Oral 150 2–3
The table is adapted from the guiding principle of JSM (http://square.umin.ac.jp/
jsm/shisin.pdf).
TABLE 6 | Recommended treatments for adult inpatients of
macrolide-resistant M. pneumoniae pneumonia.
Drug Route of
administration
mg/dose Dose/
day
First-line
drug
Minocycline (MINO) Intravenous (drip infusion) 100 2
Second-
line
drug
Levofloxacin (LVFX) Intravenous (drip infusion) 500 1
Ciprofloxacin (CPFX) Intravenous (drip infusion) 300 2
Pazufloxacin (PZFX) Intravenous (drip infusion) 500–1000 2
The table is adapted from the guiding principle of JSM (http://square.umin.ac.jp/
jsm/shisin.pdf).
values of macrolides for macrolide-sensitive M. pneumoniae
are extremely low, and the rates of bacterial elimination are
high. The MIC values of tetracyclines and tosufloxacin for
macrolide-sensitive M. pneumoniae are relatively higher than
those of macrolides. In addition, M. pneumoniae may not
be eliminated after treatment with these drugs. Tosufloxacin
is the only fluoroquinolone approved for children in Japan
(Table 7).
In children with pneumonia caused by macrolide-sensitive
M. pneumoniae, treatment with macrolides has been shown to
alleviate the fever within 48 h in more than 80% of cases. On
the other hand, fever persists in approximately 70% of children
with MRMP infection. These data indicate that the clinical
effectiveness of macrolides should be evaluated on the basis
of the presence of fever at 48–72 h after treatment. Persistent
fever suggests the possibility of infection with macrolide-
resistant strains or mixed infection with microorganisms other
than M. pneumoniae. For cases of M. pneumoniae pneumonia
with failure of macrolide treatment, either tosufloxacin or
tetracyclines are applicable. Quinolones might induce drug
resistance in the microflora other than M. pneumoniae, and
should be administered with caution. Tetracyclines may cause
side effects such as transient anostosis, staining of the teeth,
and enamel hypoplasia. Tetracyclines are contraindicated in
children aged under 8 years. The recommended duration of
treatment for M. pneumoniae pneumonia caused by macrolide-
sensitive strains is 14 days with erythromycin, 10 days with
clarithromycin, and 3 days with azithromycin. Treatment
with tosufloxacin or tetracyclines for pneumonia caused by
TABLE 7 | Recommended treatments for pediatric patients of
M. pneumoniae pneumonia.
Drug Route of
administration
Drug dose
(mg/kg/day)
Divided
dose/day
Treatment
period
(days)
Erythromycin (EM) Oral 25–50 4–6 14
Clarithromycin (CAM) Oral 10–15 2–3 10
Azithromycin (AZM) Oral 10 1 3
Tosufloxacin (TFLX) Oral 12 2 7–14
Minocycline (MINO) Oral or intravenous
drip infusion
2–4 2 7–14
The table is adapted from the guiding principle of JSM (http://square.umin.ac.jp/
jsm/shisin.pdf).
MRMPs should be administered for 7–14 days. Systemic
administration of steroids for severe pneumonia should be
considered; however, the indications of systemic steroid use are
not yet determined. One study showed that steroid therapy
is effective in patients with fever lasting >7 days, with a
serum lactate dehydrogenase level of ≥480 IU/L (Oishi et al.,
2011).
CONCLUSION
The nationwide surveillance of M. pneumoniae pneumonia
in Japan is based on reports collected from approximately
500 sentinel hospitals, and is thus not reflective of
the total number of patients. However, this weekly
monitoring can detect previous epidemics and patterns,
and has played a significant role as an alert system for
medical and public health workers as well as researchers.
Therefore, the effort for this surveillance program should be
continued.
There are two distinct genetic lineages of M. pneumoniae
that exhibit polymorphism in the cytadhesin P1 protein
sequence. However, the involvements of these two lineages in
pneumonia epidemics and differences in their pathogenicity
are not yet fully understood. Nevertheless, cytadhesin
P1 is an important factor that plays a critical role in
the infection mechanism of this pathogen and in the
interactions with host cells. We believe that p1 gene typing
is an important aspect for molecular epidemiological
studies of M. pneumoniae and should be performed by
combining modern genotyping methods based on MLVA,
multi-locus sequence typing, and/or whole-genome SNP
strategies.
Emergence of MRMP is serious problem for the
treatment of M. pneumoniae pneumonia. Given this
situation, several Japanese academic and medical societies
have issued specific guiding principles for treatment of
M. pneumoniae pneumonia. Macrolides are still recommended
as the first-line drug in children and adults. However, if
the fever does not subside in 48–72 h from first-line
drug administration, a change of antibiotics to second-
line drugs (i.e., fluoroquinolones and tetracyclines) is
recommended.
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